Formulations and methods for treating ulcerative colitis

Patent metadata

Field	Value
Publication number	US-10653744-B2
Application number	US-201716069313-A
Country	US
Kind code	B2
Filing date	Jan 11, 2017
Priority date	Jan 11, 2016
Publication date	May 19, 2020
Grant date	May 19, 2020

Abstract

This invention provides composition and methods to prevent, treat or alleviate a symptom of ulcerative colitis comprising administering to a patient dolcanatide.

First claim

We claim:

1. A method for preventing, treating, or alleviating a symptom of ulcerative colitis, the method comprising rectally administering once daily for at least 28 days to a subject in need thereof a therapeutically effective amount of a composition comprising 6 mg of dolcanatide (SEQ ID NO: 9), and inducing remission of the symptoms of ulcerative colitis in the subject.

2. The method of claim 1 , wherein the composition is administered prior to bedtime.

3. The method of claim 1 , wherein the composition is an enema.

4. The method of claim 1 , wherein the composition is a suppository.

5. The method of claim 1 , wherein the release of the composition is time dependent.

6. The method of claim 1 , wherein the composition is a liquid.

7. The method of claim 6 , wherein the liquid is saline.

Assignees

• Bausch Health Ireland Ltd

Inventors

• Shailubhai Kunwar
• Jacob Gary S
• Griffin Patrick

Classifications

• A61K38/12 Primary

  Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)} · CPC title

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title

• A61K9/0031

  Rectum, anus · CPC title

• A61K38/10

  Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title